

incubation temperature to 37°C or up to 50°C. Under such conditions, the ladders shown here could be obtained within 3 hours rather than within days.

8. C. Gaillard and F. Strauss, data not shown.
9. Cell culture (CV1 line), nuclei purification, protein extraction, gel retardation, as well as phosphocellulose, DNA-sephacryl, and hydroxyapatite chromatography were performed as described by F. Strauss and A. Varshavsky [*Cell* **37**, 889 (1984)]. Because HMG1 and HMG2 copurified on these columns, a fourth chromatographic step on carboxymethyl-cellulose was performed as described by G. H. Goodwin and E. W. Johns [*Methods in Cell Biology*, D. M. Prescott, Ed. (Academic Press, New York, 1977), vol. 16, chap. 15]. In appropriate salt conditions, HMG1 does not bind to this column, whereas HMG2 does.
10. S. Paillard and F. Strauss *Nucleic Acids Res.* **19**, 5619 (1991); T. Mimori, J. A. Hardin, J. A. Steitz, *J. Biol. Chem.* **261**, 2274 (1986).
11. E. W. Johns, Ed., *The HMG Chromosomal Proteins* (Academic Press, London, 1982); M. Bustin, D. A. Lehn, D. Landsman, *Biochim. Biophys. Acta* **1049**, 231 (1990).
12. J. M. Wright and G. H. Dixon *Biochemistry* **27**, 576 (1988); M. E. Bianchi, M. Beltrame, G. Paonessa,

*Science* **243**, 1056 (1989); M. E. Bianchi, L. Falciola, S. Ferrari, D. M. J. Lilley, *EMBO J.* **11**, 1055 (1992).

13. D. M. J. Lilley and R. M. Clegg, *Annu. Rev. Biophys. Biomol. Struct.* **22**, 299 (1993).
14. Y. Timsit, E. Westhof, R. P. P. Fuchs, D. Moras, *Nature* **341**, 459 (1989); Y. Timsit and D. Moras, *J. Mol. Biol.* **221**, 919 (1991).
15. D. B. Haniford and D. E. Pulleyblank, *J. Biomol. Struct. Dyn.* **1**, 593 (1983); H. Castleman, L. Specthrie, L. Makowski, B. F. Erlanger, *ibid.* **2**, 271 (1984).
16. J. A. Blah and R. D. Wells, *Prog. Nucleic Acid Res. Mol. Biol.* **37**, 107 (1989).
17. S. McGavin, *J. Mol. Biol.* **55**, 293 (1971); J. H. Wilson, *Proc. Natl. Acad. Sci. U.S.A.* **76**, 3641 (1979).
18. D. M. J. Lilley, *Nature* **357**, 282 (1992); K. Giese, J. Cox, R. Grosschedl, *Cell* **69**, 185 (1992); S. Ferrari *et al.*, *EMBO J.* **11**, 4497 (1992); T. T. Paull, M. J. Haykinson, R. C. Johnson, *Genes Dev.* **7**, 1521 (1993).
19. A 120-bp Cla I-Eco RI restriction fragment that contained a 60-bp tract of poly(CA)-poly(TG) was used. The nucleotide sequence of the poly(CA)-containing strand of the fragment was as follows: CGATAAGCTTCTAGAGATCCC-(CA)<sub>30</sub>-GGG-

ATCCGTCGACTCTAGAGGATCCCCGGGC-GAGCTCG.

20. Four-percent polyacrylamide gels were used. Two different electrophoresis buffers were used, with identical results [either 40 mM tris-acetate, 20 mM sodium acetate, 1 mM EDTA (pH 7.8), or 6.7 mM tris-acetate, 3.3 mM sodium acetate, 1 mM EDTA (pH 7.8) with buffer recirculation]. Identical results were obtained with gels run at 4°C or 25°C.
21. DNA spreading was done with cytochrome c on an aqueous hypophase, followed by rotary shadowing with platinum. A control, in which the same DNA was spread at a 1000-fold higher concentration without preincubation at high ionic strength to form complexes, failed to show X-shaped structures, confirming that these are not due to random crossing of DNA molecules on the electron microscope grid.
22. We thank L. Jonk, who participated in an early stage of this work, C. Antony for help with the electron microscopy facility, and S. Elsevier for critical reading of the manuscript. Supported by grants from the Association Française des Myopathes, the Association pour la Recherche contre le Cancer, and the Ligue Nationale Française Contre le Cancer.

14 December 1993; accepted 7 March 1994

## A Cell Cycle Regulator Potentially Involved in Genesis of Many Tumor Types

Alexander Kamb,\* Nelleke A. Gruis, Jane Weaver-Feldhaus, Qingyun Liu, Keith Harshman, Sean V. Tavtigian, Elisabeth Stockert, Rufus S. Day III, Bruce E. Johnson, Mark H. Skolnick

A putative tumor suppressor locus on the short arm of human chromosome 9 has been localized to a region of less than 40 kilobases by means of homozygous deletions in melanoma cell lines. This region contained a gene, Multiple Tumor Suppressor 1 (*MTS1*), that encodes a previously identified inhibitor (p16) of cyclin-dependent kinase 4. *MTS1* was homozygously deleted at high frequency in cell lines derived from tumors of lung, breast, brain, bone, skin, bladder, kidney, ovary, and lymphocyte. Melanoma cell lines that carried at least one copy of *MTS1* frequently carried nonsense, missense, or frameshift mutations in the gene. These findings suggest that *MTS1* mutations are involved in tumor formation in a wide range of tissues.

The genetics of cancer involves positive regulators of the transformed state (oncogenes) as well as negative regulators (tumor suppressor genes). More than 100 oncogenes have been characterized, and although less than a dozen tumor suppressor genes have been identified to date, the number is expected to increase beyond 50 (1). The involvement of so many genes

underscores the complexity of the growth control mechanisms that maintain the integrity of normal tissue. This complexity is manifested in another way. So far no single gene has been shown to participate in the

development of all or even the majority of human cancers. The most common oncogenic mutations are in *HRAS*, found in 10 to 15% of solid tumors (2). The most frequently mutated tumor suppressor gene is the p53 gene, mutated in roughly 50% of all tumors (3). Without a target that is common to all transformed cells, the dream of "magic bullet" that can destroy or reverse cancer cells while leaving normal tissue unharmed is improbable. The hope for a new generation of specifically targeted antitumor drugs may rest on the ability to identify tumor suppressor genes or oncogenes that play general roles in control of cell division. One of the mechanisms for controlling tumor growth might involve direct regulation of the cell cycle. Genes that control the decision to initiate DNA replication are attractive candidates for oncogenes or tumor suppressor genes depending on whether they have a stimulatory or inhibitory role in the process. Indeed, several oncogenes and tumor suppressor genes have been found to participate directly in the cell cycle. For instance, one of the cyclins, a class of proteins that promotes DNA replication

**Table 1.** Deletions in tumor cells and primary tumors.

Tumor type	Lines (n)	Deletions (n)	Deletions (%)
Astrocytoma	17	14	82
Bladder	15	5	33
Breast	10	6	60
Colon	20	0	0
Glioma	35	25	71
Leukemia	4	1	25
Lung	59	15	25
Melanoma	99	57	58
Neuroblastoma	10	0	0
Osteosarcoma	5	3	60
Ovary	7	2	29
Renal	9	5	56
Total	290	133	46

A. Kamb, N. A. Gruis, J. Weaver-Feldhaus, Q. Liu, K. Harshman, S. V. Tavtigian, Myriad Genetics, Inc., Salt Lake City, UT 84108, USA.  
 E. Stockert, Ludwig Institute for Cancer Research, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA.  
 R. S. Day III, Department of Medicine, Cross Cancer Institute, Edmonton, Alberta, Canada.  
 B. E. Johnson, Lung Cancer Biology Section, National Cancer Institute, Bethesda, MD 20889, USA.  
 M. H. Skolnick, Myriad Genetics, Inc., Salt Lake City, UT 84108, and Department of Medical Informatics, University of Utah Medical Center, Salt Lake City, UT 84108, USA.

\*To whom correspondence should be addressed.

and mitosis, has been implicated as an oncogene (4), and the retinoblastoma tumor suppressor is a substrate of the cyclin-dependent protein kinases (cdks) (5).

A hallmark of tumor suppressor genes is that they are deleted at high frequency in certain tumor types. The deletions often involve loss of a single allele, so-called loss of heterozygosity (LOH), but may also involve homozygous deletion of both alleles. For LOH, the remaining allele is presumed to be nonfunctional, either because of a preexisting inherited mutation or because of a secondary somatic mutation.

The human 9p21 region contains chromosomal inversions, translocations, heterozygous deletions, and homozygous deletions in glioma cell lines, non-small cell lung cancer lines, leukemia lines, and melanoma lines (6-8). Certain 9p21 markers are deleted in more than half of all melanoma lines (9). These findings suggest that 9p21 contains a tumor suppressor locus that may be involved in genesis of several tumor types. In a previous study, we reported the results of a YAC and P1 chromosomal walk in a region of 9p21 (9). This work produced a physical map and a set of sequence tagged sites (STSs) that were used to analyze nearly 100 melanoma cell lines for homozygous deletions. More than half of these cell lines contained homozygous deletions that clustered around a single cosmid, c5 (Fig. 1A). Fine structure mapping experiments with STSs derived from c5 revealed the presence of small, nonoverlapping, homozygous deletions of c5 sequences in six melanoma cell lines. On the basis of this result, it was probable that a tumor suppressor gene lay at least partly within cosmid c5.


To search for candidate tumor suppressor genes, the DNA sequence of parts of cosmid c5 was determined (10). When this

sequence was compared with sequences in GenBank, two distinct regions of c5 were identified that were similar to a region of a previously defined gene encoding human cdk4 inhibitor, or p16 (11). These two sequences were named Multiple Tumor Suppressor 1 (MTS1) and MTS2 (Fig. 1B).

Detailed comparison of genomic sequence from c5 with the p16 mRNA sequence revealed that MTS1 contained a stretch of 307 bp that was identical to a portion of the p16 coding sequence. This

stretch of nucleotides in MTS1 was flanked by recognizable splice junction sequences. Further characterization of MTS1 showed that it included the entire coding sequence of p16 plus two introns. The two introns divided the coding sequence of p16 into three regions: a 5' region of 126 bp (coding exon 1), a middle region of 307 bp (coding exon 2), and a 3' region of 11 bp (coding exon 3).

MTS2 contained a region of DNA sequence 93% identical to p16 sequence



**Fig. 1.** Maps of cosmid c5 region. These maps are part of a larger physical map derived from a chromosomal walk in the region (9). (A) Relevant STSs used for the deletion analysis are shown, as are cosmids and P1s mentioned in the text. The c1.b marker lies proximal to P1 1062 and is not shown. The transcriptional orientations of MTS1 and MTS2 are shown by arrows. (B) Restriction map and STS map of cosmid c5. Positions of coding exons for MTS1 and MTS2 are shown as thick bars. E1 and E2, coding exon 1 and coding exon 2, respectively; B, Bam HI; S, Sal I; R1, Eco RI; and R5, Eco RV. (C) Deletions in tumor cell lines of STSs. Positive controls and negative controls were included in every polymerase chain reaction (PCR) experiment and cell lines in which only one or two of the STSs were deleted (such as class 20) were retested at least twice. The cell lines used for this study and their class designations are available from the authors upon request. +, presence of DNA; -, absence (homozygous deletion).



letions. The single line that was heterozygous contained two nonsilent mutations, a finding consistent with the view that each homolog had undergone independent mutational events. Based on this DNA sequence and deletion analysis of *MTS1*, a minimum of 75% melanoma lines contained mutant *MTS1* or had lost the gene from both homologs.

A similar analysis of coding exon 2 from *MTS2* did not reveal any polymorphisms. In addition, no deletions unequivocally involved *MTS2* alone (Fig. 1C). When RN1.1, the marker within *MTS2*, was deleted, markers within *MTS1* were also lost with five exceptions (classes 4, 8, and 12 in Fig. 1C). However, two of these exceptional lines were shown to have *MTS1* mutations or deletions: melanoma line SK-MEL-26 (class 8) was missing coding exon 1 from *MTS1* (13) and melanoma line SK-MEL-12 (class 8) contained a hemizygous missense mutation in coding exon 2 of *MTS1* (Table 2) (13). The remaining three lines apparently did contain coding exon 1 of *MTS1*; however, it is possible that the regulatory region of *MTS1* was affected by the deletion breakpoints located upstream. Thus, the function of *MTS2* has not been resolved. The striking sequence similarity between *MTS1* and *MTS2* implies that *MTS2* may also inhibit one or more cdk's, perhaps including *cdk4*. The majority of homozygous deletions removed both *MTS1* and *MTS2*. Thus, *MTS2* may have some role in tumorigenesis. Alternatively, *MTS2* may be a nonfunctional gene or may have a role entirely different from *MTS1*.

It is possible that mutation or loss of *MTS1* is a product of cell growth in culture. However, a high percentage of primary leukemia cells also contain homozygous de-

letions of the  $\alpha$ -interferon gene cluster, a gene family located less than 500 kb from *MTS1* (8). Studies of melanoma cell lines suggest that deletions of  $\alpha$ -interferon genes invariably involve markers that extend beyond *MTS1* toward the centromere (13). In addition, LOH studies of human primary, non-small cell lung cancer and primary head and neck carcinoma have demonstrated that the minimal area of heterozygous deletion in these tumors encompasses 9p21-22 (8). Finally, nonsense and splice-junction mutations in *MTS1* have been observed in primary melanomas and bladder tumors (16). Because deletions of the 9p21 region and nonsense mutations of *MTS1* occur in primary tumor cells as well as cultured cell lines, the deletions observed in tumor cell lines are unlikely to be purely a result of cell growth in culture.

Dividing eukaryotic cells must pass through two critical decision points: the G<sub>1</sub>-S transition where DNA synthesis commences and the G<sub>2</sub>-M transition where mitosis begins. The machinery that controls cell division has multiple components, many of which are related (16). The cdk's may be at the heart of the control apparatus in that they regulate by phosphorylation a number of key substrates that in turn trigger the transition from G<sub>1</sub> to S and from G<sub>2</sub> to M. So far, four types of cdk have been defined (*cdk2-5*) that may participate in G<sub>1</sub>-S control as well as a set of positive regulators of these cdk's (for example, cyclins C, D1-3, E). Recently several negative regulators have also been identified, including p21 (p20 in mouse), and the *MTS1* gene product p16 (11, 17, 18). On the basis of in vitro studies and on its interaction with p53, p21 has been proposed as a general inhibitor of all cdk's (18). Thus, in vitro, p16 appears

more specific than p21. Both of these inhibitors are expected to antagonize entry into S phase.

If p16 inhibits *cdk4* in vivo, *cdk4* and its cyclin partners are strong candidates for oncogenes that could be major factors in tumorigenesis. The prevalence of mutations in the p16 gene suggests the possibility that *cdk4* may serve as a general activator of cell division in most, if not all, cells. Further biochemical studies of the effects of p16 on different cdk's may help clarify the hierarchy of cdk activity in both normal cells and transformed cells. Proof of our model awaits direct demonstration of the tumor suppressor function of p16 and of the interaction between p16 and *cdk4* in vivo.

REFERENCES AND NOTES

1. A. G. Knudson, *Nature Genet.* 5, 103 (1993).
2. J. A. Anderson, J. C. Irish, B. Y. Ngan, *J. Otolaryngol.* 21, 321 (1992).
3. C. C. Harris, *Science* 262, 1980 (1993).
4. G. A. Lammie *et al.*, *Oncogene* 6, 439 (1991); T. Motokura *et al.*, *Nature* 350, 512 (1991); C. L. Rosenberg *et al.*, *Proc. Natl. Acad. Sci. U.S.A.* 88, 9638 (1991); D. A. Withers *et al.*, *Mol. Cell. Biol.* 11, 4846 (1991).
5. M. E. Ewen *et al.*, *Cell* 73, 487 (1993).
6. O. I. Olopade *et al.*, *Cancer Res.* 52, 2523 (1992); R. Lukeis, L. Irving, M. Gason, S. Hasthorpe, *Genes Chromosomes Cancer* 2, 116 (1990); M. O. Diaz *et al.*, *Proc. Natl. Acad. Sci. U.S.A.* 85, 5259 (1988); P. G. Middleton *et al.*, *Leukemia* 5, 680 (1991); J. W. Fountain *et al.*, *Proc. Natl. Acad. Sci. U.S.A.* 89, 10557 (1992); O. I. Olopade *et al.*, *Cancer Res.* 53, 2410 (1993); J. Q. Cheng, S. C. Jhanwar, Y. Y. Lu, J. R. Testa, *ibid.*, p. 4761; C. D. James, J. He, V. P. Collins, M. J. Allalunis-Turner, R. S. Day, *ibid.*, p. 3674.
7. M. O. Diaz *et al.*, *N. Engl. J. Med.* 322, 77 (1990).
8. A. Merlo, E. Gabrielson, F. Askin, D. Sidransky, *Cancer Res.* 54, 640 (1994); P. van der Riet *et al.*, *ibid.*, p. 1156.
9. J. Weaver-Feldhaus *et al.*, *Proc. Natl. Acad. Sci. U.S.A.*, in press.
10. DNA sequence determination of c5 was carried out by subcloning the internal Hind III fragments and Eco RI fragments and determining the DNA sequences of these subclones independently. Primer sequence walking steps were carried out sequentially on each subcloned template. DNA sequencing reactions were performed with the PRISM Ready Reaction DyeDeoxy Terminator Cycle Sequencing kit (ABI), and the products were analyzed on an ABI 373 sequencer.
11. M. Serrano, G. J. Hannon, D. Beach, *Nature* 366, 704 (1993).
12. To exclude the possibility that the sequence divergence in coding DNA might be a cloning artifact, we designed PCR primers to amplify specifically across the sequence divergence point of *MTS2*. These primers amplified a fragment of the predicted size from cosmid, P1, and genomic DNA (15). Therefore the divergent sequence located near the 3' end of exon 2 in *MTS2* is bona fide genomic sequence.
13. A. Kamb *et al.*, unpublished data.
14. These STSs included two markers on the distal side of *MTS1* (1063.7 and c18.b), two markers within *MTS1* (c5.1, located between coding exons 2 and 3, and RN3.1, located within coding exon 2), three markers between *MTS1* and *MTS2* (c5.3, R2.3, and R2.7), one marker within *MTS2* (RN1.1, located at the 3' end of coding exon 2), and one marker on the proximal side of *MTS2* (c1.b). The method for preparation of cell line DNA has been described (9). The PCR conditions used for STS amplification were one cycle at 95°C (5 min); four cycles at 95°C (10 s) with

Table 2. Mutations in melanoma lines determined by DNA sequence analysis.

Cell line	Mutation	Coding effect	Location†
SK-MEL-61	G→A	None	258
	G→A	Gly→Ser	259
SK-MEL-21	C→T	Arg→stop	166
SK-MEL-17	G→A	Ala→Thr	436
SK-MEL-112	5-base deletion	Frameshift	284-288
SK-MEL-178	C→T	Arg→stop	232
SK-MEL-124	G→A	Trp→stop	324
SK-MEL-86	C→T	Arg→stop	232
SK-MEL-131	8-base deletion	Frameshift	166-173
SK-MEL-150(het)*	C→A	None	165
	C→T	Pro→Leu	335
	C→T	None	231
	C→T	Arg→stop	232
SK-MEL-12	C→T	Pro→Leu	335
SK-MEL-156	C→T	None	372
SK-MEL-101	G→A	Trp→stop	323
SK-MEL-158	C→T	Gln→stop	142
SK-MEL-145	2-base deletion	Frameshift	122-123

\*Het stands for heterozygote and refers to the presence in the sample of both the wild-type and mutant sequence. †The nucleotide positions of the base changes (location) derive from the numbering scheme used in Serrano *et al.* (11).

- the annealing temperature ( $T_{ann}$ ) = 68°C (10 s) and 72°C (10 s); four cycles with  $T_{ann}$  = 66°C; four cycles with  $T_{ann}$  = 64°C; four cycles with  $T_{ann}$  = 62°C; and 30 cycles with  $T_{ann}$  = 60°C. The DNA sequences of primers used for the STS analysis were 1063.7F, CCGTTTCAGCTTCTCATCAC; 1063.7R, CCGACTGTCCCATGTGATT; c18.bF, CAAAGACTTTATGATGGGG; c18.bR, TCCATTCTCTGCTTGCTC; c5.1F, GAAGTCTTGGTCTGATGTC; c5.1R, CTC-TTCTGCACAACCTCAACT; RN3.1F, GGATAGAGAACTCAAGAAGG; RN3.1R, TCTGAGCTTTGGAA-GCTCT; c5.3F, GTGGTAGAACTAGGACAGGG; c5.3R, CTGTGTAAAGCCTTCATAGA; R2.3F, GAAATGAAACTGTACCCATTG; R2.3R, GGGACACATTAAATACACT; R2.7F, GAGAACAGGTTT-TGGGAC; R2.7R, AACTAGACCTAGGGATAAGG; c1.bF, AAGCTTCCCAAACTGGC; c1.bR, AATGCCTTGGCATAAGGGAC.
15. Fragments for DNA sequence determination were amplified as described (14), except that 5% dimethyl sulfoxide was added to the reaction. The

products were purified from a 1.2% agarose gel with Qiaex beads (QIAGEN). Genomic fragments corresponding to coding exons 1 or 2 from *MTS1* or coding exon 2 from *MTS2* were amplified with specific primers and analyzed by cycle sequencing with [ $\alpha$ - $P^{32}$ ]deoxyadenosine triphosphate (19). Products were run on 6% polyacrylamide gels. All A reactions were loaded side by side, followed by the C reactions, and so on. Detection of polymorphisms was by eye with confirmation on the other strand. The DNA sequences of the primers used for amplification and sequence determination were

Coding exon 1, *MTS1*. Amplification: 2F, GAA-GAAAGAGGAGGGGCTG; 1108R, GCGCTACCTGATTCCAATTC. Sequencing: 1108R.

Coding exon 2, *MTS1*. Amplification: 42F, GG-AAATTGGAACTGGAAGC; 551R, TCTGAGCT-TTGGAAAGCTCT. Sequencing: 42F and 551R.

Coding exon 2, *MTS2*. Amplification: 89F, TGA-

GTTTAACCTGAAGGTGG; 50R, GGGTGGGAA-ATTGGGTAAG. Sequencing: 89F and 50R.

16. N. A. Gruis *et al.*, in preparation.
17. J. W. Harper, G. R. Adami, N. Wei, K. Keyomarsi, S. J. Elledge, *Cell* **75**, 805 (1993); Y. Gu, C. W. Turck, D. O. Morgan, *Nature* **366**, 707 (1993); W. S. el-Deiry, T. Tokino, V. E. Velculescu, *Cell* **75**, 817 (1993).
18. Y. Xiong *et al.*, *Nature* **366**, 701 (1993).
19. J. Sambrook, E. F. Fritsch, T. Maniatis, *Molecular Cloning: A Laboratory Manual* (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989).
20. We thank D. Ballinger, S. Bayer, J. Collet, P. Dayananth, W. Ding, C. Frye, C. Hussey, M. McClure, D. Shattuck-Eidens, S. Stone, and T. Tran for suggestions and assistance. Supported in part by NIH grant CA-48711.

17 March 1994; accepted 1 April 1994

## AAAS–Newcomb Cleveland Prize

### To Be Awarded for a Report, Research Article, or an Article Published in *Science*

The AAAS–Newcomb Cleveland Prize is awarded to the author of an outstanding paper published in *Science*. The value of the prize is \$5000; the winner also receives a bronze medal. The current competition period began with the 4 June 1993 issue and ends with the issue of 27 May 1994.

Reports, Research Articles, and Articles that include original research data, theories, or syntheses and are fundamental contributions to basic knowledge or technical achievements of far-reaching consequence are eligible for consideration for the prize. The paper must be a first-time publication of the author's own work. Reference to pertinent earlier work by the author may be included to give perspective.

Throughout the competition period, readers are

invited to nominate papers appearing in the Reports, Research Articles, or Articles sections. Nominations must be typed, and the following information provided: the title of the paper, issue in which it was published, author's name, and a brief statement of justification for nomination. Nominations should be submitted to the AAAS–Newcomb Cleveland Prize, AAAS, Room 924, 1333 H Street, NW, Washington, DC 20005, and **must be received on or before 30 June 1994**. Final selection will rest with a panel of distinguished scientists appointed by the editor of *Science*.

The award will be presented at the 1995 AAAS annual meeting. In cases of multiple authorship, the prize will be divided equally between or among the authors.